Loading data for IMDX — first visit, this takes a few seconds.
Insight Molecular Diagnos... (IMDX)
NasdaqCM: IMDX
· Real-Time Price · USD
4.36
+0.08 (1.87%)
At close: Aug 19, 2026, 2:05 PM
Insight Molecular Diagnostics Inc. (IMDX) Stock Price, Analysis & Data
1.87% (1D)
No data available
| Bid | n/a |
| Market Cap | 142.68M |
| Revenue (ttm) | 1.67M |
| Net Income (ttm) | -49.36M |
| Beta | 1.82 |
| EPS (ttm) | -1.53 |
| PE Ratio (ttm) | n/a |
| Forward PE | -5.19 |
| P/B (ttm) | -6.68 |
| P/S (ttm) | 85.44 |
| Earnings Date | Nov 9, 2026 |
| Ask | n/a |
| Volume | 7,257 |
| Avg. Volume (20D) | 246,801 |
| Open | 4.29 |
| Previous Close | 4.28 |
| Day's Range | 4.25 - 4.40 |
| 52-Week Range | 2.33 - 8.51 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About IMDX
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment...
Industry Diagnostics & Research
Sector Healthcare
IPO Date Dec 30, 2015
Employees 55
Stock Exchange NasdaqCM
Ticker Symbol IMDX
Website https://www.imdxinc.com
Financial Performance
In 2025, Insight Molecular Diagnostics's revenue was 4.05M, an increase of 115.58% compared to the previous year's 1.88M. Earnings were -50.22M, a decrease of -17.21%.
Financial StatementsEarnings Surprise
Insight Molecular Diagnostics has released their quarterly earnings on Aug 10, 2026:
Insight Molecular Diagnostics Inc. is scheduled to release its earnings on Nov 9, 2026, during market hours.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2